Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04344041
Recruitment Status : Completed
First Posted : April 14, 2020
Last Update Posted : April 30, 2021
Sponsor:
Collaborator:
Mylan Laboratories
Information provided by (Responsible Party):
University Hospital, Angers

Tracking Information
First Submitted Date  ICMJE April 9, 2020
First Posted Date  ICMJE April 14, 2020
Last Update Posted Date April 30, 2021
Actual Study Start Date  ICMJE April 15, 2020
Actual Primary Completion Date January 14, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 9, 2020)
Number of death of any cause, during the 14 days following the inclusion and intervention. [ Time Frame: Day 14 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 4, 2020)
  • Number of death of any cause, during the 28 days following the inclusion and intervention. [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19 [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Rate of patients with at least one severe adverse event at day 28, according to the regulations [ Time Frame: Day 28 ]
  • Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7 [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7 [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7 [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7 [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology [ Time Frame: Day 14 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 9, 2020)
  • Number of death of any cause, during the 28 days following the inclusion and intervention. [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19 [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Rate of patients with at least one severe adverse event at day 28, according to the regulations [ Time Frame: Day 28 ]
  • Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L) [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 14 ]
  • Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 28 ]
  • Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 14 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
  • Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L) [ Time Frame: Day 28 ]
    OSCI ranges from 0 to 8, higher score meaning poorer outcome
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
Official Title  ICMJE COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
Brief Summary

Vitamin D is a secosteroid hormone produced by the skin during Summer exposure to UVB rays. Hypovitaminosis D is common in Winter (October to March) at Northern latitudes above 20 degrees North, and from April to September at Southern latitudes beyond 20 degrees below the equator.

In the past, coronaviruses and influenza viruses have exhibited very high seasonality, with outbreaks occurring preferentially during the Winter. The Covid-19 pandemic is indeed more severe above Winter latitudes of 20 degrees, while it remains until now less severe in the Southern hemisphere, with a much lower number of deaths.

Preclinical research suggests that the SARS-Cov-2 virus enters cells via the angiotensin converting enzyme 2 (ACE2). Coronavirus viral replication downregulates ACE2, thereby dysregulating the renin-angiotensin system (RAS) and leading to a cytokine storm in the host, causing acute respiratory distress syndrome (ARDS).

Research also shows that vitamin D plays a role in balancing RAS and in reducing lung damage. On the contrary, chronic hypovitaminosis D induces pulmonary fibrosis through activation of RAS. Similarly, hypovitaminosis D has been strongly associated in the literature with ARDS, as well as with a pejorative vital prognosis in resuscitation but also in geriatric units, and with various comorbidities associated to deaths during SARS-Cov-2 infections. Conversely, vitamin D supplementation has been reported to increase immunity and to reduce inflammatory responses and the risk of acute respiratory tract infections.

High-dose oral vitamin D3 supplementation has been shown to decrease short-term mortality in resuscitation patients with severe hypovitaminosis D (17% absolute risk reduction). It is considered safe to take oral vitamin D supplementation at doses up to 10,000 IU/day for short periods, particularly in older adults, i.e. a population that is mostly affected by hypovitaminosis D and who should receive at least 1,500 IU of vitamin D daily to ensure satisfactory vitamin D status.

Vitamin D supplementation is mentioned as a potentially interesting treatment for SARS-Cov-2 infection but on a scientific basis with a low level of evidence until now.

We hypothesize that high-dose vitamin D supplementation improves the prognosis of older patients diagnosed with COVID-19 compared to a standard dose of vitamin D.

Detailed Description

• Inclusion visit A clinical examination is carried out. Social-demographic measures, health history, clinical examination measures (including OSCI score) and biological measures are collected.

Randomization is conducted on the day of the inclusion visit. The ZYMAD® 400,000 IU (2 vials of 200,000 IU) or 50,000 IU (1 vial of 50,000 IU) treatment is given to the patient.

  • Visit at day 7 A blood test is carried out by a nurse to determine the serum 25-OHD, creatrinine, albumine and calcium concentrations.
  • Visit at day 14 A visit or telephone call allows recording the onset of clinical events of interest. The drugs received as part of the usual treatment during the last 14 days are collected.
  • Visit at day 28 A visit or telephone call allows recording the onset of clinical events of interest. The drugs received as part of the usual treatment during the last 14 days are collected.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Coronavirus
Intervention  ICMJE
  • Drug: cholecalciferol 200,000 IU
    Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
  • Drug: cholecalciferol 50,000 IU
    Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
Study Arms  ICMJE
  • Experimental: Intervention group
    High dose of vitamin D3
    Intervention: Drug: cholecalciferol 200,000 IU
  • Active Comparator: Comparator group
    Standard dose of vitamin D3
    Intervention: Drug: cholecalciferol 50,000 IU
Publications * Annweiler C, Beaudenon M, Gautier J, Simon R, Dubée V, Gonsard J, Parot-Schinkel E; COVIT-TRIAL study group. COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. Trials. 2020 Dec 28;21(1):1031. doi: 10.1186/s13063-020-04928-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 9, 2020)
260
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 14, 2021
Actual Primary Completion Date January 14, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥ 65 years old
  • Infection with COVID-19 diagnosed with RT-PCR SARS-CoV-2 or withCT-scan of the chest suggesting viral pneumonia of peripheral predominance in a clinically relevant context
  • Patient seen in hospitalization or consultation or in nursing home
  • Diagnosed within the preceding 3 days
  • Having at least one of the following two risk factors for complications:

    • age ≥75 years
    • Peripheral capillary oxygen saturation (SpO2) ≤ 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg
  • Patients affiliated with or benefitting from a social security scheme
  • Written and signed consent of the patient or a relative or legal representative or, if not possible, emergency inclusion procedure

Exclusion Criteria:

  • Organ failure requiring admission to a resuscitation or high dependency unit
  • Comorbidity that is life-threatening in the short-term (life expectancy <3 months)
  • Any reason that makes follow-up at day 28 impossible
  • Vitamin D supplementation in the previous month, with the exception of treatment providing less than 800 IU of vitamin D per day
  • Contraindication for vitamin D supplementation: active granulomatosis (sarcoidosis, tuberculosis, lymphoma), history of calcic lithiasis, known hypervitaminosis D or hypercalcemia, known intolerance to vitamin D
  • Participation in another simultaneous trial
  • Safeguard of justice
  • Peripheral capillary oxygen saturation (SpO2) ≤92% in spite of an oxygen therapy > 5L/min
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 65 Years and older   (Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04344041
Other Study ID Numbers  ICMJE 2020-001602-34
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University Hospital, Angers
Study Sponsor  ICMJE University Hospital, Angers
Collaborators  ICMJE Mylan Laboratories
Investigators  ICMJE Not Provided
PRS Account University Hospital, Angers
Verification Date April 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP